Phase I clinical trial combining imatinib mesylate and IL-2 in refractory cancer patients: IL-2 interferes with the pharmacokinetics of imatinib mesylate

OncoImmunology

Volumn 2, Issue 2, 2013, Pages

  Pautier, Patricia ^a   Locher, Clara ^a,b,c   Robert, Caroline ^a   Deroussent, Alain ^a,d   Flament, Caroline ^a,b   Le Cesne, Axel ^a   Rey, Annie ^a   Bahleda, Ratislav ^a   Ribrag, Vincent ^a   Soria, Jean Charles ^a,c   Vassal, Gilles ^a,c   Eggermont, Alexander ^a,c   Zitvogel, Laurence ^a,b,c   Chaput, Nathalie ^a   Paci, Angelo ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b INSERM   (France)

^c UNIVERSITÉ PARIS SACLAY   (France)

^d CNRS   (France)

Author keywords

Cancer; Imatinib mesylate; Interleukin 2; Maximum tolerate dose; Pharmacokinetics

Indexed keywords

2 [2 METHYL 5 [4 (1 PIPERAZINYLMETHYL)BENZAMIDO]ANILINO] 4 (3 PYRIDYL)PYRIMIDINE; CYCLOPHOSPHAMIDE; IMATINIB; INTERLEUKIN 2; PROLEUKINE; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CAPILLARY LEAK SYNDROME; CHILL; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; COUGHING; DIARRHEA; DISEASE DURATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG EFFICACY; DRUG FEVER; DRUG HALF LIFE; DRUG POTENTIATION; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DYSPNEA; EDEMA; FATIGUE; FEMALE; FLUID RETENTION; HEMATOLOGIC DISEASE; HUMAN; LEUKOPENIA; LOW DRUG DOSE; LYMPHOCYTOPENIA; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SIDE EFFECT; SKIN DISEASE; SOLID TUMOR; TIME TO MAXIMUM PLASMA CONCENTRATION;

EID: 84886943675     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.23079     Document Type: Article

References (45)

1. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med PMID:8616716; http://dx.doi.org/10.1038/nm0596-561, 1996; 2:561-6.
2. Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N, et al.; IRIS Investigators. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med PMID:17151364; http://dx.doi. org/10.1056/NEJMoa062867, 2006; 355:2408-17.
3. Buchdunger E, Cioffi CL, Law N, Stover D, Ohno-Jones S, Druker BJ, et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther PMID:10991971, 2000; 295:139-45.
4. Dewar AL, Doherty KV, Hughes TP, Lyons AB. Imatinib inhibits the functional capacity of cultured human monocytes. Immunol Cell Biol PMID:15661041; http://dx.doi.org/10.1111/j.1440-1711.2004.01296.x, 2005; 83:48-56.
5. Fabian MA, Biggs WH 3rd, Treiber DK, Atteridge CE, Azimioara MD, Benedetti MG, et al. A small moleculekinase interaction map for clinical kinase inhibitors. Nat Biotechnol, PMID:15711537; http://dx.doi.org/10.1038/nbt1068, 2005; 23:329-36.
6. Guo J, Marcotte PA, McCall JO, Dai Y, Pease LJ, Michaelides MR, et al. Inhibition of phosphorylation of the colony-stimulating factor-1 receptor (c-Fms) tyrosine kinase in transfected cells by ABT-869 and other tyrosine kinase inhibitors. Mol Cancer Ther, PMID:16648572; http://dx.doi. org/10.1158/1535-7163.MCT-05-0359, 2006; 5:1007-13.
7. Joensuu H, Roberts PJ, Sarlomo-Rikala M, Andersson LC, Tervahartiala P, Tuveson D, et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med, PMID:11287975; http://dx.doi.org/10.1056/NEJM200104053441404, 2001; 344:1052-6.
8. Pardanani A, Ketterling RP, Brockman SR, Flynn HC, Paternoster SF, Shearer BM, et al. CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy. Blood, PMID:12842979; http://dx.doi. org/10.1182/blood-2003-05-1627, 2003; 102:3093-6.
9. Pardanani A, Reeder T, Li C-Y, Tefferi A. Eosinophils are derived from the neoplastic clone in patients with systemic mastocytosis and eosinophilia. Leuk Res, PMID:12860006; http://dx.doi. org/10.1016/S0145-2126(03)00065-1, 2003; 27:883-5.
10. Borg C, Terme M, Taïeb J, Menard C, Flament C, Robert C, et al. Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects. J Clin Invest, PMID:15286804, 2004; 114:379-88.
11. Delahaye NF, Rusakiewicz S, Martins I, Meacute;nard C, Roux S, Lyonnet L, et al. Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors. Nat Med, PMID:21552268; http://dx.doi.org/10.1038/nm.2366, 2011; 17:700-7.
12. Menard C, Blay J-Y, Borg C, Michiels S, Ghiringhelli F, Robert C, et al. Natural killer cell IFN-gamma levels predict long-term survival with imatinib mesylate therapy in gastrointestinal stromal tumor-bearing patients. Cancer Res, PMID:19351841; http://dx.doi.org/10.1158/0008-5472.CAN-08-3807, 2009; 69:3563-9.
13. Mignot G, Ullrich E, Bonmort M, Menard C, Apetoh L, Taieb J, et al. The critical role of IL-15 in the antitumor effects mediated by the combination therapy imatinib and IL-2. J Immunol, PMID:18453565, 2008; 180:6477-83.
14. Taieb J, Chaput N, Menard C, Apetoh L, Ullrich E, Bonmort M, et al. A novel dendritic cell subset involved in tumor immunosurveillance. Nat Med, PMID:16444265; http://dx.doi. org/10.1038/nm1356, 2006; 12:214-9.
15. Ullrich E, Bonmort M, Mignot G, Jacobs B, Bosisio D, Sozzani S, et al. Trans-presentation of IL-15 dictates IFN-producing killer dendritic cells effector functions. J Immunol, PMID:18523252, 2008; 180:7887-97.
16. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst, PMID:10655437; http://dx.doi. org/10.1093/jnci/92.3.205, 2000; 92:205-16.
17. O'Brien SG, Meinhardt P, Bond E, Beck J, Peng B, Dutreix C, et al. Effects of imatinib mesylate (STI571, Glivec) on the pharmacokinetics of simvastatin, a cytochrome p450 3A4 substrate, in patients with chronic myeloid leukaemia. Br J Cancer, PMID:14612892; http://dx.doi.org/10.1038/sj.bjc.6601152, 2003; 89:1855-9.
18. Pollack IF, Jakacki RI, Blaney SM, Hancock ML, Kieran MW, Phillips P, et al. Phase I trial of imatinib in children with newly diagnosed brainstem and recurrent malignant gliomas: a Pediatric Brain Tumor Consortium report. Neuro Oncol, PMID:17293590; http://dx.doi. org/10.1215/15228517-2006-031, 2007; 9:145-60.
19. Gustavson LE, Nadeau RW, Oldfield NF. Pharmacokinetics of teceleukin (recombinant human interleukin-2) after intravenous or subcutaneous administration to patients with cancer. J Biol Response Mod, PMID:2787839, 1989; 8:440-9.
20. Kirchner GI, Franzke A, Buer J, Beil W, Probst-Kepper M, Wittke F, et al. Pharmacokinetics of recombinant human interleukin-2 in advanced renal cell carcinoma patients following subcutaneous application. Br J Clin Pharmacol, PMID:9690943; http://dx.doi.org/10.1046/j.1365-2125.1998.00036.x, 1998; 46:5-10.
21. Obeid M, Tesnière A, Ghiringhelli F, Fimia GM, Apetoh L, Perfettini J-L, et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med, PMID:17187072; http://dx.doi. org/10.1038/nm1523, 2007; 13:54-61.
22. Lotze MT, Custer MC, Sharrow SO, Rubin LA, Nelson DL, Rosenberg SA. In vivo administration of purified human interleukin-2 to patients with cancer: development of interleukin-2 receptor positive cells and circulating soluble interleukin-2 receptors following interleukin-2 administration. Cancer Res, PMID:3030546, 1987; 47:2188-95.
23. Carson WE, Haldar S, Baiocchi RA, Croce CM, Caligiuri MA. The c-kit ligand suppresses apoptosis of human natural killer cells through the upregulation of bcl-2. Proc Natl Acad Sci U S A, PMID:7519782; http://dx.doi.org/10.1073/pnas.91.16.7553, 1994; 91:7553-7.
24. Sunman JA, Hawke RL, LeCluyse EL, Kashuba ADM. Kupffer cell-mediated IL-2 suppression of CYP3A activity in human hepatocytes. Drug Metab Dispos, PMID:14977871; http://dx.doi. org/10.1124/dmd.32.3.359, 2004; 32:359-63.
25. Liptrott NJ, Penny M, Bray PG, Sathish J, Khoo SH, Back DJ, et al. The impact of cytokines on the expression of drug transporters, cytochrome P450 enzymes and chemokine receptors in human PBMC. Br J Pharmacol, PMID:19154420; http://dx.doi.org/10.1111/j.1476-5381.2008.00050.x, 2009; 156:497-508.
26. Hosten B, Abbara C, Cibert M, Petit B, Farinotti R, Gonin P, et al. Interleukin-2 treatment effect on imatinib pharmacokinetic, P-gp and BCRP expression in mice. Anticancer Drugs, PMID:20016370; http://dx.doi.org/10.1097/CAD.0b013e3283349913, 2010; 21:193-201.
27. Ettinghausen SE, Moore JG, White DE, Platanias L, Young NS, Rosenberg SA. Hematologic effects of immunotherapy with lymphokine-activated killer cells and recombinant interleukin-2 in cancer patients. Blood, PMID:3495302, 1987; 69:1654-60.
28. Ettinghausen SE, Lipford EH 3rd, Mule JJ, Rosenberg SA. Systemic administration of recombinant interleukin 2 stimulates in vivo lymphoid cell proliferation in tissues. J Immunol, PMID:3891854, 1985; 135:1488-97.
29. Lenardo MJ. Interleukin-2 programs mouse alpha beta T lymphocytes for apoptosis. Nature, PMID:1944559; http://dx.doi. org/10.1038/353858a0, 1991; 353:858-61.
30. Zheng L, Trageser CL, Willerford DM, Lenardo MJ. T cell growth cytokines cause the superinduction of molecules mediating antigen-induced T lymphocyte death. J Immunol, PMID:9551911, 1998; 160:763-9.
31. Yardley DA, Burris HA 3rd, Markus T, Spigel DR, Greco FA, Mainwaring M, et al. Phase II trial of docetaxal plus imatinib mesylate in the treatment of patients with metastatic breast cancer. Clin Breast Cancer, PMID:19933079; http://dx.doi.org/10.3816/CBC.2009.n.040, 2009; 9:237-42.
32. Maurel J, Martins AS, Poveda A, Lopez-Guerrero JA, Cubedo R, Casado A, et al. Imatinib plus lowdose doxorubicin in patients with advanced gastrointestinal stromal tumors refractory to high-dose imatinib: a phase I-II study by the Spanish Group for Research on Sarcomas. Cancer, PMID:20564079; http://dx.doi.org/10.1002/cncr.25111, 2010; 116:3692-701.
33. Matei D, Emerson RE, Schilder J, Menning N, Baldridge LA, Johnson CS, et al. Imatinib mesylate in combination with docetaxel for the treatment of patients with advanced, platinum-resistant ovarian cancer and primary peritoneal carcinomatosis: a Hoosier Oncology Group trial. Cancer, PMID:18618737; http://dx.doi.org/10.1002/cncr.23605, 2008; 113:723-32.
34. Dugan E, Truax R, Meadows KL, Nixon AB, Petros WP, Favaro J, et al. A phase I dose-escalation study of imatinib mesylate (Gleevec/STI571) plus capecitabine (Xeloda) in advanced solid tumors. Anticancer Res, PMID:20530436, 2010; 30:1251-6.
35. Ali Y, Lin Y, Gharibo MM, Gounder MK, Stein MN, Lagattuta TF, et al. Phase I and pharmacokinetic study of imatinib mesylate (Gleevec) and gemcitabine in patients with refractory solid tumors. Clin Cancer Res, PMID:17908982; http://dx.doi. org/10.1158/1078-0432.CCR-07-0883, 2007; 13:5876-82.
36. Polite BN, Desai AA, Manchen B, Stadler WM. Combination therapy of imatinib mesylate and interferon-alpha demonstrates minimal activity and significant toxicity in metastatic renal cell carcinoma: results of a single- institution phase II trial. Clin Genitourin Cancer, PMID:16729911; http://dx.doi.org/10.3816/CGC.2006.n.007, 2006; 4:275-80.
37. Heinrich MC, Owzar K, Corless CL, Hollis D, Borden EC, Fletcher CDM, et al. Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group. J Clin Oncol, PMID:18955451; http://dx.doi.org/10.1200/JCO.2008.17.4284, 2008; 26:5360-7.
38. Chen LL, Chen X, Choi H, Sang H, Chen LC, Zhang H, et al. Exploiting antitumor immunity to overcome relapse and improve remission duration. Cancer Immunol Immunother, PMID:22198309; http://dx.doi.org/10.1007/s00262-011-1185-1, 2012; 61:1113-24.
39. Balachandran VP, Cavnar MJ, Zeng S, Bamboat ZM, Ocuin LM, Obaid H, et al. Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido. Nat Med, PMID:21873989; http://dx.doi. org/10.1038/nm.2438, 2011; 17:1094-100.
40. Picard S, Titier K, Etienne G, Teilhet E, Ducint D, Bernard M-A, et al. Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood, PMID:17192396; http://dx.doi.org/10.1182/blood-2006-07-036012, 2007; 109:3496-9.
41. Larson RA, Druker BJ, Guilhot F, O'Brien SG, Riviere GJ, Krahnke T, et al.; IRIS (International Randomized Interferon vs STI571) Study Group. Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood, PMID:18256322; http://dx.doi.org/10.1182/blood-2007-10-116475, 2008; 111:4022-8.
42. Singh N, Kumar L, Meena R, Velpandian T. Drug monitoring of imatinib levels in patients undergoing therapy for chronic myeloid leukaemia: comparing plasma levels of responders and non-responders. Eur J Clin Pharmacol, PMID:19214491; http://dx.doi.org/10.1007/s00228-009-0621-z, 2009; 65:545-9.
43. Demetri GD, Wang Y, Wehrle E, Racine A, Nikolova Z, Blanke CD, et al. Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors. J Clin Oncol, PMID:19451435; http://dx.doi.org/10.1200/JCO.2008.20.4818, 2009; 27:3141-7.
44. Ghiringhelli F, Menard C, Terme M, Flament C, Taieb J, Chaput N, et al. CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner. J Exp Med, PMID:16230475; http://dx.doi. org/10.1084/jem.20051511, 2005; 202:1075-85.
45. Casares N, Pequignot MO, Tesnière A, Ghiringhelli F, Roux S, Chaput N, et al. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J Exp Med, PMID:16365148; http://dx.doi.org/10.1084/jem.20050915., 2005; 202:1691-701.